FLOC's $200M Valiant deal adds ESPs to its lift lineup, expanding Permian reach and enabling end-to-end support as wells mature.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
FLOC's $200M Valiant deal adds ESPs to its lift lineup, expanding Permian reach and enabling end-to-end support as wells mature.
CLB's Q1 earnings meet estimates but fall Y/Y as a revenue miss and Middle East disruptions weigh on both key segments.
NOV Q1 earnings miss estimates as Middle East disruptions hit operations, while revenues edge past expectations despite a year-over-year decline.
Core Laboratories (NYSE:CLB) executives said first-quarter 2026 results were significantly affected by geopolitical and weather-related disruptions, with the escalation of military conflict in the Middle East creating meaningful project delays, halting some hydrocarbon production, and disrupting mar